RTP-026 is under clinical development by ResoTher Pharma and currently in Phase I for Myocardial Infarction. According to GlobalData, Phase I drugs for Myocardial Infarction have an 89% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how RTP-026’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
RTP-026 is under development for the treatment of myocardial infarction and stroke. The drug candidate is a 48 AA peptide and an analogue of RTP-025. The drug candidate is derived from the endogenous immunomodulator Annexin 1A as resolution therapy. It is administered through intravenous route and acts by targeting formyl peptide receptor 2 (FPR2).
ResoTher Pharma overview
ResoTher Pharma(ResoTher) is a Denmark based biotechnology company. The company is engaged in the manufacture of peptide-based drugs derived from the endogenous immunomodulator Annexin A1. The Annexin A1 is used for treating neutrophil-driven inflammation. ResoTher also develops drugs for treating cardiovascular disorders. A biotechnology company which focuses on developing novel and effective peptide therapeutics for cardiovascular disease by targeting inflammation. Its products includes Biotechnology, Drug Development, and Pharmaceutical Industry. ResoTher is headquartered in Holte, Denmark.
For a complete picture of RTP-026’s drug-specific PTSR and LoA scores, buy the report here.